Diametric Capital LP Takes $42,000 Position in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Diametric Capital LP bought a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 26,224 shares of the company’s stock, valued at approximately $42,000.

Several other institutional investors have also bought and sold shares of CRBU. JPMorgan Chase & Co. raised its position in Caribou Biosciences by 475.9% in the 4th quarter. JPMorgan Chase & Co. now owns 2,495,922 shares of the company’s stock valued at $3,969,000 after purchasing an additional 2,062,563 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Caribou Biosciences by 6.5% in the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock valued at $3,980,000 after buying an additional 124,782 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Caribou Biosciences by 19.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after buying an additional 118,325 shares during the last quarter. FMR LLC grew its holdings in Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after acquiring an additional 109,606 shares during the last quarter. Finally, Thrivent Financial for Lutherans increased its position in Caribou Biosciences by 74.4% in the 4th quarter. Thrivent Financial for Lutherans now owns 186,621 shares of the company’s stock valued at $297,000 after acquiring an additional 79,636 shares in the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

CRBU opened at $0.86 on Thursday. The firm has a market capitalization of $80.08 million, a PE ratio of -0.52 and a beta of 2.34. Caribou Biosciences, Inc. has a 52-week low of $0.72 and a 52-week high of $4.92. The business’s 50-day simple moving average is $1.19 and its 200 day simple moving average is $1.68.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. On average, research analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

CRBU has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Caribou Biosciences in a research note on Wednesday, March 19th. Bank of America lowered their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.